Business Wire

Milliken & Company Marks Five Years of Progress in 2022 Sustainability Report, “FOR HUMANKIND”

Share

Diversified global manufacturer Milliken & Company released its fifth annual sustainability report, “For HumanKind,” today. The report tracks Milliken’s progress on its 2025 Sustainability Goals, originally set in 2019, and provides initial baseline data for its net-zero targets, formally verified in 2022. The report showcases how sustainability impacts Milliken’s business today and is integral to the company’s future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005301/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Milliken's sustainability report, entitled "For HumanKind," shares five years of progress on the company's sustainability goals. (Photo: Business Wire)

Milliken’s announcement of its short- and long-term targets to reach net-zero by 2050 added a new dimension to its sustainability effort. Milliken is one of the first 50 companies in the world, and the first in South Carolina, to have science-based targets approved by the U.N.- backed Science Based Targets initiative (SBTi). These targets joined 12 other sustainability goals Milliken set forth to guide its work with its people, its products and the planet through the lens of human benefit and science.

“It’s been inspiring to see what we’ve accomplished in just a few years. We know we can continue this progress as we rally our associates, our shareholders, our partners, and our customers to be a part of the solution to the world’s most pressing challenges, including climate change,” says Milliken President and CEO Halsey Cook. “Our work is far from over, and we know that teamwork is the key to accelerating the innovation that will unlock success–not only for ourselves, but for all of humankind.”

Also in 2022, Milliken announced it would phase out the use of PFAS in its fibers and finishes within its textile portfolio, completing this exit in December 2022. In line with its commitment to end-of-life solutions for plastics, Milliken’s corporate foundation—the Milliken & Company Charitable Foundation—invested in The Recycling Partnership’s Center for Sustainable Behavior and Impact, which offers tangible solutions for increasing recycling rates in U.S. households. Diversity among Milliken’s U.S. management team is up 10% since 2018, representing 36% gender diversity and 17% racial/ethnic diversity. Notably, Milliken also met its goal for a 25% reduction in indexed greenhouse gas emissions in its operations this year and will now focus on greater GHG emission reductions in line with its net-zero targets.

“Our sustainability efforts continue to evolve, as the shift from our greenhouse gas emissions goal to the more holistic net-zero targets shows,” adds Milliken SVP and General Counsel Kasel Knight. “We’re proud of what we accomplished in 2022, and we’re confident that we’ll improve our efforts with new opportunities to live our purpose of positively impacting the world for generations to come.”

Milliken’s 2022 Sustainability Report can be found at milliken.com/sustainability, alongside additional net-zero resources and prior years’ reports.

About Milliken

Milliken & Company is a global manufacturing leader whose focus on materials science delivers tomorrow’s breakthroughs today. From industry-leading molecules to sustainable innovations, Milliken creates products that enhance people’s lives and deliver solutions for its customers and communities. Drawing on thousands of patents and a portfolio with applications across the textile, specialty chemical, flooring and healthcare businesses, the company harnesses a shared sense of integrity and excellence to positively impact the world for generations. Discover more about Milliken’s curious minds and inspired solutions at milliken.com and on Facebook, Instagram, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Betsy Sikma
betsy.sikma@milliken.com
864.909.7908

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye